Original Research Article

Septicemia in neonates admitted to NICU with special reference to Acinetobacter species

Ruturaj M Kolhapure¹, A. Ravi Shankar Reddy¹,*, Raj Kumar H.R.V¹

¹Dept. of Microbiology, Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, Telangana, India

ARTICLE INFO

Article history:
Received 28-04-2019
Accepted 24-06-2019
Available online 09-09-2019

Keywords:
Acinetobacter
Neonates
Septicemia

ABSTRACT

Introduction: Acinetobacter species are opportunistic pathogen, which are gaining importance in hospital acquired neonatal septicemia due to multidrug resistance and causing increased morbidity as well as mortality.

Materials and Methods: A prospective analysis was performed over a period of 6 months. Blood samples from neonates suspected of sepsis were collected and culture was done using conventional techniques. Acinetobacter when isolated were identified up to species level and drug sensitivity pattern of those isolate were done. Risk factors leading to Acinetobacter septicemia were also studied.

Results: Out of 200 blood culture samples, 12(17.1%) Acinetobacter species were isolated, among these the predominant isolate was 7(58.3%) Acinetobacter baumannii, followed by Acinetobacter calcoaceticus 3(25%) and 1(8.3%) each were A.lwofii and A.hemolyticus. All isolates were resistant to 3 or more group of drugs.

Conclusion: Neonatal septicemia especially with MDR Acinetobacter is on the rise and is associated with increased morbidity and mortality. Continuous surveillance of isolates from neonatal septicemia, adherence to infection control policies and rational antibiotic usage will reduce the incidence of such infections.

1. Introduction

The genus Acinetobacter, now a member of family Moraxellaceae, consists of 25 DNA homology groups or genomospecies. Only 11 have been officially named; the two species most commonly seen in clinical specimens are Acinetobacter baumannii complex, the glucose-oxidizing non-hemolytic strain, and A.lwoffii, the glucose-negative, non-hemolytic strain. Most hemolytic strains are A.hemolyticus. Acinetobacter are ubiquitous in environment in soil, water, and foodstuffs. In the hospital environment, they have been associated with ventilators, humidifiers, catheters, and other devices.

About 25% of adults carry the organism on their skin, and about 7% carry the organism in their pharynx. If not already harboring Acinetobacter spp., hospitalized patients become easily colonized. In the past, when Acinetobacter spp. were isolated from nonsterile sites such as urine and many different types of respiratory specimens, they were usually considered insignificant colonizers or contaminants. However, with increased isolates of Acinetobacter that demonstrate resistance to most antimicrobial agents, including the carbapenems, their clinical significance when isolated from blood culture, cannot be dismissed as contaminants.

Acinetobacter spp. are opportunists, accounting for 3-5% of all hospital acquired infections; they are second only to P.aeruginosa in frequency of isolation of all nonfermenters in clinical microbiology lab.¹

All Acinetobacter spp. are strictly aerobic, and they appear as gram-negative cocciococci or even gram-negative cocci on Gram stain. Acinetobacter species can also appear as gram-positive cocci in smear made from blood culture bottles.¹

Septicemia in neonates is a significant cause of morbidity and mortality in developing countries. Common isolates are Klebsiella spp. Staphylococcus aureus, Pseudomonas spp., and Enterobacter spp.. Acinetobacter species are important
potential pathogens in neonatal sepsis because of frequent colonization of ICUs and multi-drug resistance.\(^2,3\)

A number of studies have reported the risk factor of infections from resistant strains of Acinetobacter species like prior antibiotic use, longer duration of intensive care unit stay, preterm birth, birth weight <1500 g.\(^3,4\)

The present study shows importance of Acinetobacter spp. as pathogen in neonatal blood stream infection. Identification of risk factors for Acinetobacter septicemia and antibiotic susceptibility testing were other objectives.

2. Materials and Methods

This prospective study was conducted in the department of Microbiology at Kamineni Institute of Medical Sciences, Narketpally, Telangana, over a period of 6 months from April 2013 to September 2013. The present study included 200 blood culture samples from suspected neonatal septicemia cases admitted to NICU. Samples were collected with aseptic precautions. These were processed using conventional bacteriological procedure for isolation of Acinetobacter species. Blood specimens were cultured using manual blood culture bottles containing 20ml of brain heart infusion broth with sps (sodium polyanetholsulphonate 0.025%). 1ml of blood was inoculated with all due precautions. Blood cultures were considered negative only after 7 days of incubation.

Gram stain was carried out after 24 hours of incubation, followed by inoculation onto blood agar and MacConkey agar, and incubated aerobically for 24 hours at 37\(^0\) C.

Acinetobacter species identification was made with the help of phenotypic criteria by Gerner-Smidt, they included parameters like Gram stain, colony morphology, penicillin susceptibility, oxidase, catalase and urease activity, citrate reduction, glucose and lactose oxidative utilization, chloramphenicol sensitivity, and growth at 37\(^0\) C and 44\(^0\) C.\(^5\) Antibiotic susceptibility testing was done by conventional disc diffusion method according to CLSI guidelines.\(^6\) Antibiotic discs used were Piperacillin (100 \(\mu g\)), Ampicillin- sulbactam (10/10 \(\mu g\)), Ceftazidine (30\(\mu g\)), Piperacillin-tazobactam Imipenem (10\(\mu g\)), Meropenem (10\(\mu g\)), Gentamicin (10\(\mu g\)), Amikacin (30\(\mu g\)), Netilmicin (30\(\mu g\)), Ciprofloxacin (5\(\mu g\)), Colistin (10\(\mu g\)) and Co-trimoxazole (1.25/23.75 \(\mu g\)).

ATCC 25922 Escherichia coli was used for quality control of anti biotic susceptibility testing.\(^6\)

In the present study MDR Acinetobacter species would be defined as resistant to at least three groups of antibiotic agents such as penicillins and cephalosporins (including beta lactam inhibitor combination), fluoroquinolones, and aminoglycosides.

3. Results

Out of 200 blood culture samples included in the study, 70(35\%) were positive for aerobic bacteriological culture. Out of which 12(17.1\%) were due to Acinetobacter species. Among these 7(58.3\%) were Acinetobacter baumanii, 3(25\%) were Acinetobacter calcoaceticus and 1(8.3\%) each were A.lwofii and A.hemolyticus. Table 1.

The main risk factors associated with Acinetobacter neonatal septicemia were, hospital births (100\%), birth weight <1500 g (75\%), preterm birth (58.3\%), prolonged intravenous antibiotic use (83.3\%) and prolonged hospital stay (66.6\%). Table 2.

All the 12(17.1\%) isolates were resistant to 3 or more group of drugs (Multi-drug resistant strain). The resistant percentage among various drugs were Piperacillin (100\%), Ampicillin- sulbactam (58.3\%), Ceftazidine (100\%), Piperacillin-tazobactam (100/10 \(\mu g\)) (91.6\%), Imipenem (58.3\%), Meropenem (58.3\%), Gentamicin (100\%), Amikacin (100\%), Netilmicin (66.6\%), Ciprofloxacin (100\%) and Co- trimoxazole (100\%), Colistin (0\%). Table 3.

A high degree of resistant pattern was seen to various groups of antibiotics. All Acinetobacter baumannii complex (A.baumannii + A.calcoaciticus) isolate showed resistant to multiple group of antibiotics. All Acinetobacter baumannii isolates were resistant to Carbapenems (58.3\%). In comparison, both A.lwofii and A.hemolyticus were more susceptible to antibiotics used in the study. Many isolates showed increased sensitivity to Ampicillin- sulbactam, probably due to intrinsic sensitivity of Acinetobacter species to sulbactam. In our study we also saw increase in netilmicin sensitivity (33.4\%), among carbapenem resistant Acinetobacter baumannii isolates, for reasons unknown.

Table 1: Species of Acinetobacter isolated (n=12)

<table>
<thead>
<tr>
<th>Acinetobacter species</th>
<th>No. of isolates</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acinetobacter baumannii</td>
<td>7</td>
<td>58.3%</td>
</tr>
<tr>
<td>Acinetobacter calcoaceticus</td>
<td>3</td>
<td>25%</td>
</tr>
<tr>
<td>Acinetobacter lwoffi</td>
<td>1</td>
<td>8.3%</td>
</tr>
<tr>
<td>Acinetobacter haemolyticus</td>
<td>1</td>
<td>8.3%</td>
</tr>
<tr>
<td>Total</td>
<td>12</td>
<td>100%</td>
</tr>
</tbody>
</table>

Table 2: Risk factors for Neonatal sepsis (n=12)

<table>
<thead>
<tr>
<th>Risk Factors</th>
<th>No. of Neonates (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital birth</td>
<td>12 (100%)</td>
</tr>
<tr>
<td>Preterm birth</td>
<td>7 (58.3%)</td>
</tr>
<tr>
<td>Birth weight &lt;1500 g</td>
<td>9 (75%)</td>
</tr>
<tr>
<td>Prolonged hospital stay</td>
<td>8 (66.6%)</td>
</tr>
<tr>
<td>Prolonged intravenous antibiotic use</td>
<td>10 (83.3%)</td>
</tr>
</tbody>
</table>
Table 3: Resistant pattern of Acinetobacter species against various antimicrobial agents

<table>
<thead>
<tr>
<th>Antibiotics</th>
<th>A.baumannii (n=7)</th>
<th>A.calcoaceticus (n=3)</th>
<th>A.lwoffii (n=1)</th>
<th>A.hemolyticus (n=1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Piperacillin</td>
<td>7 (100%)</td>
<td>3 (100%)</td>
<td>1 (100%)</td>
<td>1 (100%)</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>7 (100%)</td>
<td>3 (100%)</td>
<td>1 (100%)</td>
<td>1 (100%)</td>
</tr>
<tr>
<td>Amikacin</td>
<td>7 (100%)</td>
<td>3 (100%)</td>
<td>1 (100%)</td>
<td>1 (100%)</td>
</tr>
<tr>
<td>Netilmicin</td>
<td>3 (42.85%)</td>
<td>2 (66.6%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ceftazidime</td>
<td>7 (100%)</td>
<td>3 (100%)</td>
<td>1 (100%)</td>
<td>1 (100%)</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>7 (100%)</td>
<td>3 (100%)</td>
<td>1 (100%)</td>
<td>1 (100%)</td>
</tr>
<tr>
<td>Ampicillin-Sulbactam</td>
<td>3 (42.85%)</td>
<td>2 (66.6%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Piperacillin-Tazobactam</td>
<td>7 (100%)</td>
<td>3 (100%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Imipenem</td>
<td>5 (71.4%)</td>
<td>2 (66.6%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Meropenem</td>
<td>5 (71.4%)</td>
<td>2 (66.6%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Co-trimoxazole</td>
<td>7 (100%)</td>
<td>3 (100%)</td>
<td>1 (100%)</td>
<td>1 (100%)</td>
</tr>
<tr>
<td>Colistin</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

4. Discussion

Acinetobacter species has evolved as an important opportunistic pathogen in healthcare settings, globally. It has remarkable ability to acquire multiple antibiotic resistance and to survive for prolonged periods under various environmental conditions, due to which it causes frequent hospital outbreaks. The common targets are critically ill patients with breach in skin integrity causing pneumonia, urinary tract infection, wound infection and septicemia.1–3,7

MDR Acinetobacter sp. septicemia in neonates is associated with high mortality. The present study was undertaken to find incidence and antibiotic resistance pattern of Acinetobacter sp. in neonatal septicemia.

In our study Acinetobacter neonatal septicemia incidence was 17.1%. This was similar to the studies conducted by Asifa Nazir (13.7%), Vinodkumar et al (9%), Arora (12.3%), and Mondal et al. (15.2%).8–11 A.baumannii complex was the predominant species in our study (83.3%). This was similar in other studies like Nariz et al (98%), De AS et al (84.6%), Vinodkumar et al (91.2%). This percentage was however lower in other studies like Arora et al (56.52%), Mondal et al (60%).

In this study, Acinetobacter sepsis was found more in low birth weight babies (75%) and preterm babies (58.3%), which was similar to other studies. Nazir et al low birth weight (81.6%), De AS et al (65.3%). Preterm babies with sepsis in other studies were Nazir et al (77.5%), De AS et al (69.1).10–12 It was also matching with other studies.8,9,11 Preterm infants have up to 3-5 fold higher risk of infection that full term infants as they are on prolonged intravenous drugs, ventilator support, or other invasive procedure that provides an opportunity for Acinetobacter species to gain entry. In this study increase in Acinetobacter septicemia was noted with prolonged ICU stay (66.6%). Other studies did not show such high relation between prolonged stay and increased Acinetobacter infection, Nazir et al (45%), De AS et al (38.4%). Based on this findings it is important that we strengthen our infection control practices.

All Acinetobacter baumannii 7(100%) strains were resistant to Carbapenems, similar pattern was noticed from other studies Nazir et al. MDR Acinetobacter is reported globally and causes most difficult HAIs to treat. MDR Acinetobacter species percentage in our study was 11(91.6%), Nazir et al also showed similar results (95.9%), other studies showed low MDR percentage among Acinetobacter species De AS et al (53.75%).12

5. Conclusion

Neonatal septicemia especially with MDR Acinetobacter is on the rise and is associated with increased morbidity and mortality. Continuous surveillance of isolates from neonatal septicemia, adherence to infection control policies and rational antibiotic usage will reduce the incidence of such infections. Since all babies had clinical features suggestive of sepsicaemia, the organism was considered to be significant. Acinetobacter spp is an important pathogen of nosocomial septicemia in neonates. Source of infection for outbreaks of Acinetobacter septicemia have been traced to medical equipment, emphasizing the need for special attention to disinfection of shared items and extra care with respiratory care and wound care. Rational antibiotic use along with implementation of infection control policies are required for control of such infections.

6. Source of Funding

None.

7. Conflict of Interest

None.

References


6. Clinical and Laboratory Standards Institute. ; 2012.,


**Author biography**

Ruturaj M Kolhapure Assistant Professor

A. Ravi Shankar Reddy Professor

Raj Kumar H.R.V Professor and HOD

---

**Cite this article:** Kolhapure RM, Reddy ARS, Kumar H.R.V R. Septicemia in neonates admitted to NICU with special reference to Acinetobacter species. *Indian J Microbiol Res* 2019;6(3):241–244.